158 related articles for article (PubMed ID: 37468570)
1. Diagnostic yield of a risk model versus faecal immunochemical test only: a randomised controlled trial in a colorectal cancer screening programme.
Kortlever TL; van der Vlugt M; Duijkers FAM; Masclee A; Kraaijenhagen R; Spaander MCW; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E
Br J Cancer; 2023 Sep; 129(5):791-796. PubMed ID: 37468570
[TBL] [Abstract][Full Text] [Related]
2. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
[TBL] [Abstract][Full Text] [Related]
3. One or two faecal immunochemical tests in an organised population-based colorectal cancer screening programme in Murcia (Spain).
Tourne-Garcia C; Perez-Riquelme F; Monteagudo-Piqueras O; Fraser CG; Yepes-Garcia P
J Med Screen; 2022 Dec; 29(4):231-240. PubMed ID: 35578555
[TBL] [Abstract][Full Text] [Related]
4. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
[TBL] [Abstract][Full Text] [Related]
5. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
[TBL] [Abstract][Full Text] [Related]
7. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
[TBL] [Abstract][Full Text] [Related]
8. Addition of an online, validated family history questionnaire to the Dutch FIT-based screening programme did not improve its diagnostic yield.
Roos VH; Kallenberg FGJ; van der Vlugt M; Bongers EJC; Aalfs CM; Bossuyt PMM; Dekker E
Br J Cancer; 2020 Jun; 122(12):1865-1871. PubMed ID: 32307443
[TBL] [Abstract][Full Text] [Related]
9. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
[TBL] [Abstract][Full Text] [Related]
10. Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial.
Sali L; Ventura L; Mascalchi M; Falchini M; Mallardi B; Carozzi F; Milani S; Zappa M; Grazzini G; Mantellini P
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1016-1023. PubMed ID: 36116454
[TBL] [Abstract][Full Text] [Related]
11. One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening: a cross-sectional study in China.
Wang L; Chen H; Zhu Y; Lu M; Wang Y; Chen X; Ma W; Du L; Chen W
BMJ Open; 2022 May; 12(5):e059754. PubMed ID: 35589365
[TBL] [Abstract][Full Text] [Related]
12. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
[TBL] [Abstract][Full Text] [Related]
13. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
14. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
[TBL] [Abstract][Full Text] [Related]
15. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
16. Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model.
Meester RGS; van de Schootbrugge-Vandermeer HJ; Breekveldt ECH; de Jonge L; Toes-Zoutendijk E; Kooyker A; Nieboer D; Ramakers CR; Spaander MCW; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; Nagtegaal ID; Dekker E; van Leerdam ME; Lansdorp-Vogelaar I;
Gut; 2023 Jan; 72(1):101-108. PubMed ID: 35537811
[TBL] [Abstract][Full Text] [Related]
17. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
[TBL] [Abstract][Full Text] [Related]
18. Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland.
Sarkeala T; Färkkilä M; Anttila A; Hyöty M; Kairaluoma M; Rautio T; Voutilainen M; Helander S; Jäntti M; Lehtinen M; Patrikka L; Malila N; Heinävaara S
BMJ Open; 2021 Feb; 11(2):e046667. PubMed ID: 33558363
[TBL] [Abstract][Full Text] [Related]
19. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]